Clopidogrel versus Other Antiplatelet Agents in the Secondary Prevention of Vascular Events in Adults with Cerebrovascular Disease: Clinical and Cost-Effectiveness Analyses

CADTH’s health technology assessment report on clopidogrel versus other antiplatelet agents examines the clinical efficacy and cost-effectiveness of this treatment strategy for secondary prevention of vascular events in adults with cerebrovascular disease. The report also assesses current clinical practice guidelines and the health services impact of different antiplatelet therapies.

Report

This complete report has been extensively peer-reviewed by external clinical and methodological experts.

Summaries